Promising new pill for cystic fibrosis

STRIVE research team, including Canadian CF researchers Drs. Felix Ratjen and Liz Tullis, published ground-breaking results in the November 3, 2011, edition of The New England Journal of Medicine. Treatment with KALYDECO^TM, a new medicine that targets the malfunctioning protein in people with cystic fibrosis, lead to significant health benefits in people with the G551D mutation. Read more.

Reviewed/updated: 2011-11-04